Licogliflozin versus placebo in women with polycystic ovary syndrome ( PCOS ): a randomised, double‐blind, phase 2 trial

2021 ◽  
Author(s):  
S Tan ◽  
S Ignatenko ◽  
F Wagner ◽  
A Dokras ◽  
J Seufert ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Phase 2 ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Phase 2 Trial

Licogliflozin versus Placebo in Women with Polycystic Ovary Syndrome (PCOS): A Randomised, Double-Blind, Phase 2 Trial

2021 ◽  
Author(s):  
Susanne Tan ◽  
Stanislav Ignatenko ◽  
Frank Wagner ◽  
Anuja Dokras ◽  
Jochen Seufert ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Phase 2 ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Phase 2 Trial

Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial

2008 ◽  
Vol 89 (5) ◽  
pp. 1221-1228 ◽  
Author(s):  
Åsa Lindholm ◽  
Marie Bixo ◽  
Inger Björn ◽  
Pål Wölner-Hanssen ◽  
Mats Eliasson ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Weight Reduction ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial

2011 ◽  
Vol 95 (5) ◽  
pp. 1849-1852 ◽  
Author(s):  
Nazia Raja-Khan ◽  
Allen R. Kunselman ◽  
Cynthia S. Hogeman ◽  
Christy M. Stetter ◽  
Laurence M. Demers ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Vascular Function ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Ovary Syndrome ◽  
Double Blind

scholarly journals Atorvastatin Increases 25-Hydroxy Vitamin D Concentrations in Patients with Polycystic Ovary Syndrome

2010 ◽  
Vol 56 (11) ◽  
pp. 1696-1700 ◽  
Author(s):  
Thozhukat Sathyapalan ◽  
John Shepherd ◽  
Charlotte Arnett ◽  
Anne-Marie Coady ◽  
Eric S Kilpatrick ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Statin Treatment ◽  
Vitamin D Supplementation ◽  
Significant Rise ◽  
Controlled Study ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Markers Of Inflammation

BACKGROUND It has been shown that many women with polycystic ovary syndrome (PCOS) are 25-hydroxyvitamin D (25OHD) insufficient. Both statin treatment and vitamin D supplementation have been shown to improve biochemical hyperandrogenemia, insulin resistance, and markers of inflammation in patients with PCOS, raising the possibility that some of the statin effects are mediated through vitamin D. METHODS We conducted this randomized, double-blind placebo controlled study to assess the effect of atorvastatin on serum 25OHD concentrations in patients with PCOS. Forty medication-naive patients with PCOS were randomized to either atorvastatin 20 mg daily or placebo for 3 months. After completing the initial 3 months of atorvastatin or placebo, both groups of patients participated in a 3-month extension study with metformin 1500 mg daily. We measured changes in 25OHD concentrations by use of tandem mass spectrometry. RESULTS Mean (SD) baseline 25OHD concentrations were comparable between the 2 groups [45.9 (2.4) vs 44.8 (1.8) nmol/L; P = 0.7]. There was a significant increase in 25OHD concentrations with atorvastatin [45.9 (2.4) vs 60.8 (3.5) nmol/L] compared with placebo [44.8 (1.8) vs 41.8 (3.2) nmol/L; P = 0.02]. Three-month treatment with metformin maintained the improvement of 25OHD with atorvastatin compared to baseline [45.9 (2.4) vs 61.8 (3.5), P ≤ 0.01). There were no significant changes in 25OHD concentrations in the placebo group after 12 weeks of metformin. CONCLUSIONS Among patients with polycystic ovary syndrome, 12 weeks of atorvastatin led to a clinically significant rise in 25OHD concentrations. This may represent a beneficial pleiotropic effect of statins on 25OHD concentrations.

Sign in / Sign up

Export Citation Format

Share Document